Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 2 | BMC Neurology

Figure 2

From: Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension

Figure 2

Clinical and magnetic resonance imaging (MRI) endpoints over months 0–12. Between-groups comparisons for (A) proportions of patients who were free of new/newly enlarged T2 lesions, (B) proportions of patients who were relapse-free (absolute number of patients free of confirmed relapses), (C) the cumulative number of new/newly enlarged T2 lesions and (D) the annualized relapse rate (calculated as total number of confirmed relapses per treatment arm divided by total number of days on the study for all patients per treatment arm, multiplied by 365.25). The MRI analysis population was used for the proportion of patients free of new/newly enlarged T2 lesions (A) and cumulative number of new/newly enlarged T2 lesions (C). The extension full analysis set was used for the proportion of patients relapse-free (B) and annualized relapse rate (D).

Back to article page